Russia's sovereign wealth fund, the Russian Direct Investment Fund (RDIF), has said it has agreed to supply 100 million doses of its COVID-19 vaccine, Sputnik-V, to Indian drug company Dr Reddy's Laboratories, as Moscow speeds up plans to distribute its vaccine abroad, Reuters news agency reported on Wednesday.
This deal comes after the RDIF reached agreements with Indian manufacturers to produce 300 million doses of the vaccine in India, which is a major consumer of Russian oil and arms.
RDIF said in a statement that Dr Reddy's, one of India's top pharmaceutical companies, will carry out Phase III clinical trials of the vaccine in India, pending regulatory approval, adding that deliveries to India could begin in late 2020, subject to the completion of trials and the vaccine's registration by regulatory authorities in India.
G V Prasad, co-chairman of Dr Reddy's, was cited in the RDIF statement as saying that the Phase I and II results had shown promise adding, "Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India."
However, there was no detail about the price of the vaccine but RDIF has said previously it was not aiming at making a profit, just covering costs.
According to Reuters, Russia was the first country to license a COVID-19 vaccine before large-scale Phase III trials were complete, stirring concern among scientists and doctors about the safety and efficacy of the shot.
Reportedly, the RDIF has already reached vaccine supply deals with Kazakhstan, Brazil and Mexico. It has also signed a memorandum with the Saudi
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine